Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Zegerid Articles

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld

6 September 2012

FDA setback for S-P and Santarus' Zegerid

19 January 2009

Santarus gets $2.5M milestone from S-P for OTC Zegerid

2 June 2008

Santarus developing new Zegerid formulation

2 June 2008

Zegerid launched in P Rico and Virgin Is

25 February 2008

Santaurus and GSK in licensing deal

10 December 2007

Santarus gets $5M milestone form S-P

3 September 2007

Santarus Zegerid: better NAB control than Nexium/Prevacid

29 May 2006

DDW 2006 sees presentations on new and established IBS drugs and advances in Crohn's

29 May 2006

Santarus launches Zegerid caps in USA

3 April 2006

TAP terminates sub-license deal with Santarus

16 January 2006

Santarus gains on positive Zegerid trial data

20 June 2005

Santarus submits NDA to US FDA for chewable Zegerid

6 June 2005

Santarus files NDA with US FDA for Zegerid

9 May 2005

Santarus EPS drop of $3.30 in 2004

4 April 2005

Santarus: Zegerid tablets trials a success

14 February 2005

Santarus' Zegerid available in the USA

11 October 2004

Santarus initiates pivotal trial of Zegerid

30 August 2004

Santarus submits NDA for new Zegerid tablet

Showing 1-19 of 19 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS